Navigation Links
New discovery reveals fate of nanoparticles in human cells
Date:9/22/2009

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have uncovered what happens to biomimetic nanoparticles when they enter human cells. They found that the important proteins that make up the outer layer of these nanoparticles are degraded by an enzyme called cathepsin L. Scientists now have to take this phenomenon into account and overcome this process to ensure the exciting field of nanomedicine can progress. The research is published today (22 September) in ACS Nano.

Dr Raphal Lvy, a BBSRC David Phillips Fellow at the University of Liverpool and lead researcher on the project said: "We've known for some time that nanoparticles are taken into cells and there have been experiments done to establish their final destinations, but we didn't know until now what state they are in by the time they get there."

In most biological applications, nanoparticles are coated with a layer of molecules, often proteins, which determine the use of nanoparticles when they enter cells. The researchers have confirmed, in a wide range of cells, that nanoparticles are taken into a region called the endosome, where this essential coating is degraded by cathepsin L.

Dr Violaine Se, also a BBSRC David Phillips Fellow at the University of Liverpool, and joint corresponding author, added: "One of the promising applications of nanoparticles in medicine is to use them as a method to deliver therapeutic protein molecules inside cells. For these biological therapies to be effective the proteins have to be maintained with high integrity and unfortunately we have seen this compromised by the degrading action of cathepsin L."

The design of any intracellular nanodevice must now take into account the possibility of cathepsin L degradation and either bypass the endosome area all together or have some built-in inhibition of the enzyme.

Dr Lvy continued: "The methods we have developed will help with this as we can now measure the location and the state of the nanoparticle quickly and quantitatively."

Professor Douglas Kell, BBSRC Chief Executive said: "Nanotechnology is an interesting area that has the potential to push all sorts of technological boundaries. There is promise of some useful applications in biology and we've already seen some excellent results with the development of nanomagnetic technology to guide therapeutic proteins and DNA to specific sites to treat tumours, for example. Fundamental bioscience research such as this, helps drive forward nanomedicine to ensure it has a real impact on health and wellbeing in the future."


'/>"/>

Contact: Nancy Mendoza
press.office@bbsrc.ac.uk
44-179-341-3355
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Related biology technology :

1. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
2. CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
3. StoredIQ Shares Expertise at IQPCs eDiscovery Pharma, Biotech and Medical Device Conference
4. Alzheimers Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program
5. PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration
6. PTC Therapeutics Announces Drug Discovery Collaboration With Roche
7. ChemBridge Corporation and Collaborative Drug Discovery Announce Strategic Collaboration to Provide Diverse Chemical Libraries Together With Researchers Own Private Data
8. Alzheimers Drug Discovery Foundation Hosts 10th International Conference on Alzheimers Drug Discovery - September 14-15
9. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
10. Discovery of natural odors could help develop mosquito repellents
11. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... (PRWEB) , ... June 27, 2016 , ... Parallel ... clinical trials, announced today the Clinical Reach Virtual Patient Encounter CONSULT module ... circle with the physician and clinical trial team. , Using the CONSULT module, patients ...
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... ... is pleased to announce the launch of their brand, UP4™ Probiotics, into Target ... over 35 years, is proud to add Target to its list of well-respected ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
(Date:4/14/2016)... Israel , April 14, 2016 ... Authentication and Malware Detection, today announced the appointment of ... assumed the new role. Goldwerger,s leadership appointment ... on the heels of the deployment of its platform ... BioCatch,s behavioral biometric technology, which discerns unique cognitive and ...
Breaking Biology News(10 mins):